French health authorities confirmed on Wednesday the first positive case of Ebola virus disease identified on national territory. The patient, a doctor who had been working in one of the active transmission zones in the Democratic Republic of the Congo, was isolated immediately upon arrival in mainland France and transferred under strict biosafety protocols to a specialist facility equipped with negative-pressure isolation. The ministry stated the individual is in stable condition, and an epidemiological investigation is under way to trace contacts, who will be required to observe a 21-day home isolation under medical supervision. The European Centre for Disease Prevention and Control assesses the risk to the general European population as very low.

The case is linked to the outbreak declared in DRC on 15 May, though retrospective analysis suggests the Bundibugyo strain of the virus had been circulating undetected for weeks earlier. This is the seventeenth Ebola outbreak recorded in DRC, but the first caused by the rare Bundibugyo species, for which no approved vaccine or treatment currently exists. Existing vaccines developed for the Zaire strain are not effective against it. As of 24 June, DRC’s national public health institute had confirmed 1,003 cases and 254 deaths, with the eastern province of Ituri accounting for more than 90 percent of infections. Cases have also been confirmed in North Kivu and South Kivu, and across the border in Uganda, where the World Health Organization reports 20 infections and two deaths.

Viewed from Geneva, WHO officials note that the outbreak has recorded the largest number of confirmed cases within its first month of any Ebola episode, and modelling by the US Centers for Disease Control and Prevention indicates it could become the largest on record. The response is complicated by armed conflict in eastern DRC, where the M23 rebel group controls large areas, limiting access for health workers and contact tracers. Africa CDC and US public health authorities have both warned of the outbreak’s potential scale. A US citizen infected in DRC was treated in Germany and discharged after testing negative, and Washington has provided doses of an experimental antibody drug for use in trials. Russian health officials have stated that a vaccine candidate against the Bundibugyo strain has been developed but must still pass through required testing phases.

The French health ministry has reinforced a dedicated monitoring system for aid workers returning from the affected region. The immediate milestone is the completion of contact tracing and the 21-day surveillance period for exposed individuals. WHO estimates that developing and approving a vaccine specific to the Bundibugyo strain could take six to nine months. Meanwhile, containment efforts in DRC face the dual challenge of insecurity and community resistance, with the true extent of transmission likely understated due to limited surveillance in remote and conflict-affected zones.